18 results with keyword: 'allogeneic stem transplantation young patients diagnosed multiple myeloma'
The incidence of acute and chronic graft-versus-host disease in multiple myeloma patients subjected to allogeneic stem cell transplantation GVHD Schilling et al... from the
N/A
: Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a
N/A
If Aboriginal and Torres Strait Islander childhood mortality (across ages 0–14 years) were to fall to the same rates experienced by the Australian population as a whole in
N/A
Union York In the Central Pennsylvania Region, 50 STEM occupations have been identified and each of the sub-regions has been evaluated for their potential STEM employment
N/A
Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation:
N/A
The evidence for autologous hematopoietic stem cell transplantation (HSCT) for upfront treatment in patients who have newly diagnosed multiple myeloma includes several
N/A
dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II
N/A
Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case- matched study from the European Group for Blood and
N/A
Particularly for younger and fit patients with newly diagnosed multiple myeloma (NDMM), the melphalan high-dose chemotherapy (HDCT) with autologous stem cell transplantation
N/A
Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma.. A phase II trial of
N/A
Harousseau, J.L., et al., Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma:
N/A
followed by autologous stem cell transplantation, VRD consolidation and lenalidomide maintenance in newly diagnosed multiple myeloma patients: primary results of the IFM 2008 phase
N/A
Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase
N/A
Even if allogeneic stem cell transplantation has not found its definitive role in the treatment of multiple myeloma, our understanding of the immunological interaction of myeloma
N/A
Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: result of an IFM phase
N/A
High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem- cell
N/A
Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II
N/A